GSK announced the discontinuation of its Camlipixant program for refractory chronic cough after the drug failed to meet statistical significance in two Phase III clinical trials (CALM-1 and CALM-2). This represents a significant setback for GSK's pipeline and a loss of potential future revenue from a promising therapeutic area.
GSK has decided to stop further development of Camlipixant, its investigational drug for refractory chronic cough, following the failure of its 25mg twice-daily dose to achieve statistical significance in two pivotal Phase III trials, CALM-1 and CALM-2. This is a significant blow to GSK's respiratory pipeline, as Camlipixant was considered a potential blockbuster. The news will likely lead to a negative short-term reaction in GSK's stock as investors re-evaluate the company's future growth prospects and the value of its R&D efforts. For traders, this represents a clear negative catalyst for GSK, potentially opening up short opportunities or prompting a re-evaluation of long positions, while competitors in the respiratory space might see a slight, indirect positive sentiment due to reduced competition.